Clinical trials: Demyelinating Diseases
Multiple Sclerosis, Secondary Progressive
Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis
This study will assess the efficacy and safety of MBP8298 compared to placebo in subjects with Secondary Progressive Multiple Sclerosis (SPMS)
- Trial name
- MAESTRO-03 (NCT00468611)
- Testing
- MBP8298
- Volunteers
- 510 people
- Sponsor
- BioMS Technology Corp.
Multiple Sclerosis
Characterization of White Blood Cells Sub-populations From Multiple Sclerosis Patients.
Multiple sclerosis (MS) is a chronic progressive neurological autoimmune disease, that gradually affects patient's quality of life. There are about 2.5 millions patients world wide, with an increasing cost Burdon.
- Trial name
- NCT03486665
- Testing
- Blood Sampling, CSF Sampling
- Where
- Israel
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Bioimmunate
Secondary Progressive Multiple Sclerosis
Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)
The purpose of this study was to understand whether participants could mount an immune response to SARS-CoV-2 modRNA vaccines administered either during continuous siponimod treatment or during a treatment break versus while on…
- Trial name
- AMA-VACC (NCT04792567)
- Testing
- BAF312, Baseline disease modifying therapies (DMTs), BNT162
- Where
- 10 sites in Germany
- Volunteers
- 41 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Neuropathic Pain
A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis
To investigate the ability of Sativex to relieve central neuropathic pain in multiple sclerosis subjects.
- Trial name
- NCT01604265
- Testing
- Sativex
- Where
- United Kingdom
- Volunteers
- 66 people
- Sponsor
- Jazz Pharmaceuticals
Relapsing Remitting Multiple Sclerosis RRMS
A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®
This was a 3-year, prospective, multi-center, open-label study to describe the long term changes of optical coherence tomography (OCT) parameters in RRMS patients under treatment with Fingolimod.
- Trial name
- PASSOS (NCT01705236)
- Testing
- Fingolimod
- Where
- 10 sites in Germany, Switzerland
- Volunteers
- 87 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing-remitting Multiple Sclerosis
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
Primary Objectives: To assess the efficacy of vatelizumab compared to placebo as measured by a reduction in new contrast-enhancing lesions (CELs) in relapsing remitting multiple sclerosis (RRMS) patients.
- Trial name
- EMPIRE (NCT02222948)
- Testing
- Vatelizumab
- Where
- 32 sites in United States, Canada and 3 more
- Volunteers
- 112 people
- Sponsor
- Genzyme, a Sanofi Company
Relapsing Remitting Multiple Sclerosis (RRMS)
Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod
This study evaluated disease control during different lengths of treatment transition from natalizumab to fingolimod.
- Trial name
- TOFIINGO (NCT01499667)
- Testing
- Fingolimod
- Where
- 44 sites in Australia, Austria and 9 more
- Volunteers
- 142 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Relapsing-Remitting
Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis
The purpose of this study is to evaluate the efficacy and safety of Ocrelizumab produced by CinnaGen compared with Ocrevus® (Roche, Switzerland) in subjects with relapsing remitting multiple sclerosis (RRMS).
- Trial name
- NCT04966338
- Testing
- Ocrelizumab (CinnaGen, Iran), Ocrelizumab (Roche, Switzerland)
- Where
- 15 sites in Iran
- Volunteers
- 170 people
- Sponsor
- Cinnagen
Multiple Sclerosis, Clinically Isolated Syndrome
Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX)
REFLEXION is a double blind extension of the study 27025 (NCT00404352) (REFLEX). The purpose of the study is to obtain long-term follow-up data in subjects with clinically definite multiple sclerosis (MS) and subjects with a…
- Trial name
- REFLEXION (NCT00813709)
- Testing
- RNF
- Where
- 57 sites in Argentina, Austria and 22 more
- Volunteers
- 402 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Canavan Disease
A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)
The main objective of this trial is to evaluate the safety, tolerability, and pharmacodynamic activity of BBP-812, an investigational AAV9-based gene therapy, in pediatric participants with Canavan disease.
- Trial name
- NCT04998396
- Testing
- AAV9 BBP-812
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Aspa Therapeutics
Relapsing-remitting Multiple Sclerosis (RRMS)
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
The purpose of this study was to demonstrate that at least one dose (0.5 mg followed by 0.25 mg) of fingolimod is superior to glatiramer acetate 20 mg SC in reducing the ARR up to 12 months in patients with relapsing-remitting MS
- Trial name
- ASSESS (NCT01633112)
- Testing
- fingolimod, glatiramer acetate
- Where
- 130 sites in United States, Argentina and 5 more
- Volunteers
- 1,064 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Remitting Multiple Sclerosis (RRMS)
ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS
The exploratory ELIOS study aims to assess the value of novel investigational Eye Movement Biomarkers (EMBs) in tracking disease-related changes among a real-world cohort of Canadian patients with active RRMS, within the context…
- Trial name
- ELIOS (NCT06733922)
- Testing
- ETNATM-ProgMS
- Where
- 14 sites in Canada
- Volunteers
- 224 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
BENEFIT Extension Study
To assess the long-term effects of early therapeutic intervention, i.e. within two years following a first clinical demyelinating event suggestive of MS.
- Trial name
- NCT00544037
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 18 sites in Austria, Belgium and 16 more
- Volunteers
- 283 people
- Sponsor
- Bayer
Progressive Multifocal Leukoencephalopathy
Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML)
The primary objective of the study was to explore whether mefloquine can delay or stop progression of progressive multifocal leukoencephalopathy (PML) as measured by JC virus (human polyomavirus or JCV) deoxyribonucleic acid…
- Trial name
- NCT00746941
- Testing
- mefloquine
- Where
- 12 sites in United States, Brazil and 3 more
- Volunteers
- 37 people
- Sponsor
- Biogen
Multiple Sclerosis
EPID Multiple Sclerosis Pregnancy Study
Multiple Sclerosis (MS) is the most common chronic neurologic disability in young adult females in their childbearing ages. Little evidence is available regarding the association between exposure to IFN-beta (β) products and…
- Trial name
- NCT02749396
- Testing
- Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG, Extavia (interferon beta-1b), Novartis Pharma AG, Rebif (interferon beta-1a), Merck Serono Europe Ltd
- Where
- Finland
- Volunteers
- 2,089 people, healthy volunteers welcome
- Sponsor
- Bayer
Multiple Sclerosis
Effectiveness of a Digital Health Application for Multiple Sclerosis (Levidex)
The trial aims to evaluate the effectiveness of a novel digital health application (levidex), which was designed to increase quality of life in persons with multiple sclerosis (MS).
- Trial name
- LAMONT (NCT06090305)
- Testing
- levidex, Control, treatment as usual (TAU)
- Where
- Germany
- Volunteers
- 470 people
- Sponsor
- Gaia AG
Multiple Sclerosis
Rebif® Pregnancy Registry
The objective for establishing the Rebif® Pregnancy Registry is to collect prospective outcomes data on women in the United States and Canada who have been exposed to Rebif® during their pregnancies.
- Trial name
- NCT00338741
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- EMD Serono
Neurodegenerative Diseases, Osteoarthritis
Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions
To evaluate for any adverse effects that may be related to the administration and reception of autologous adipose derived stromal vascular fraction (SVF).
- Conditions
- Neurodegenerative Diseases, Osteoarthritis, Erectile Dysfunction, Autoimmune Diseases
- Trial name
- NCT01953523
- Testing
- Administration of autologous adipose derived SVF
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Elliot Lander
Multiple Sclerosis
Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis
This is a multicentre non-interventional study aimed at evaluating the real-world effectiveness and safety of ocrelizumab treatment in participants with relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis…
- Trial name
- MuSicalE (NCT03593590)
- Testing
- Ocrelizumab
- Where
- 158 sites in Austria, Belgium and 23 more
- Volunteers
- 1,710 people
- Sponsor
- Hoffmann-La Roche
Progressive Multiple Sclerosis
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
The main purpose of this study is to assess the efficacy of RO7268489 in adults with progressive multiple sclerosis (PMS) receiving ocrelizumab.
- Trial name
- Mintaka (NCT07282574)
- Testing
- RO7268489, Ocrelizumab
- Where
- 114 sites in Australia, Brazil and 10 more
- Volunteers
- 360 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.